Loading, Please Wait...
BEVERLY, Mass. and TORONTO, May 01, 2019 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading worldwide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced the introduction of its Dynamic Targeting System™ (DTS) option for its next generation LYKOS laser system for the In-vitro Fertilization clinical market.
Hamilton Thorne’s LYKOS DTS hardware and software options, coupled with the recently updated Laser 6 software and 5-megapixel digital camera, offer users computer-controlled accuracy and enhanced ease of use through:
David Wolf, President and Chief Executive Officer, stated, “The LYKOS DTS option provides clinicians with state-of-the-art automation features in the same small form factor that they have been using for years. By integrating the steering elements inside the microscope objective, we have maintained the ease of installation that our customers have come to expect, while being the only truly portable laser system for IVF clinics on the market. Our targeting software provides the user with the flexibility to automate the laser system in just the way they want. The introduction of our LYKOS DTS reflects our continued commitment to providing our customers with the most up-to-date technology to better serve their patients.”
Hamilton Thorne will display the new LYKOS DTS technology at the Asia Pacific Initiative on Reproduction (ASPIRE) 2019 Congress May 2-5, 2019. Please visit us at the Hong Kong Convention and Exhibition Centre, Booth A9.
The LYKOS DTS option will be available for purchase in select markets worldwide beginning in May 2019.
Hamilton Thorne has patents pending to protect the unique features of the DTS system in the US and internationally.
About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com
For more information, please contact:
|David Wolf, President & CEO||Michael Bruns, CFO|
|Hamilton Thorne Ltd.||Hamilton Thorne Ltd.|
Bristol Investor Relations